Email this article Effect of metformin alone and in combination with etoposide and epirubicin on proliferation, apoptosis, necrosis, and migration of B-CPAP and SW cells as thyroid cancer cell lines
, Ramin Ebrahimi Kiasari, Faezeh Pakzad, Soroush Sardari Abstract
Background and purpose: There has not been a comprehensive study on the simultaneous effects of metformin, etoposide, and epirubicin on thyroid cancer cells. Hence, the current research proposed the in vitro study on the effect of metformin alone and in combination with etoposide and epirubicin on the rate of proliferation, apoptosis, necrosis, and migration against B-CPAP and SW-1736 cells as thyroid cancer cell lines.
Experimental approach: MTT-based proliferation assay, combination index method, flow cytometry, and scratch wound healing assays were used to evaluate the simultaneous effects of the three approved drugs against thyroid cancer cells.
Findings/Results: This study showed that the toxic concentration of metformin on normal Hu02 cells was more than 10 folds higher than B-CPAP and SW cancerous cells. Metformin in combination with epirubicin and etoposide could increase percentages of B-CPAP and SW cells in early and late apoptosis and necrosis phases in comparison with their single concentrations, significantly. Metformin in combination with epirubicin and etoposide could arrest the S phase in B-CPAP and SW cells, significantly. Metformin in combination with epirubicin and etoposide could reduce ~100% migration rate, whereas single concentrations of epirubicin and etoposide could reduce ~50% migration rate.
Conclusion and implication: Combined treatment of metformin with anticancer drugs epirubicin and etoposide can increase the mortality in thyroid cancer cell lines and reduce the toxicity of these drugs on the normal cell line, which could be the starting point for proposing a new combination strategy in the therapy of thyroid cancer to induce more potency and reduce acute toxicity.
Keywords
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. DOI: 10.3322/caac.21660.
Radu TG, Ciurea ME, Mogoanta SS, Busuioc CJ, Grosu F, Tenovici M, et al. Papillary thyroid cancer stroma - histological and immunohistochemical study. Rom J Morphol Embryol. 2016;57:801-809. PMID: 27833974.
Hoskin PJ, Harmer C. Chemotherapy for thyroid cancer. Radiother Oncol.1987;10(3):187-194. DOI: 10.1016/s0167-8140(87)80004-x.
Massart C, Barbet R, Genetet N, Gibassier J. Doxorubicin induces Fas-mediated apoptosis in human thyroid carcinoma cells. Thyroid. 2004;14(4):263-270. DOI: 10.1089/105072504323030915.
Santini F, Bottici V, Elisei R, Montanelli L, Mazzeo S, Basolo F, et al. Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer. J Clin Endocrinol Metab. 2002,87(9):4160-4165. DOI: 10.1210/jc.2001-011151.
Karpinich NO, Tafani M, Rothman RJ, Russo MA, Farber JL. The course of etoposide-induced apoptosis from damage to DNA and p53 activation to mitochondrial release of cytochrome c. J Biol Chem. 2002;277(19):16547-16552. DOI: 10.1074/jbc.M110629200.
Panomuppakarn N, Witoonpanich P, Waisayarat J, Jiarpinitnun C, Ativitavas T, Ngamphaiboon N. Uncommon response of cisplatin and etoposide for treatment of advanced medullary thyroid carcinoma. Clin Case Rep. 2017;5(10):1628-1633. DOI: 10.1002/ccr3.1123.
Bayat Mokhtari, R Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, et al. Combination therapy in combating cancer. Oncotarget. 2017;8:38022-38043. DOI: 10.18632/oncotarget.16723
Meng X, Xu S, Chen G, Derwahl M, Liu Ch. Metformin and thyroid disease. J Endocrinol. 2017;233:R43-R51. DOI: 10.1530/JOE-16-0450.
Courtois S, Dura´n R, Giraud J, Sifre´ E, Izotte J, Me´graud F, et al. Metformin targets gastric cancer stem cells. Eur J Cancer. 2017;84:193-201. DOI: 10.1016/j.ejca.2017.07.020.
Rena G, Hardie G, Pearson E. The mechanisms of action of metformin. Diabetologia. 2017;60(9):1577-1585. DOI: 10.1007/s00125-017-4342-z.
El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000;275:223-228. DOI: 10.1074/jbc.275.1.223.
Shaw RJ. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol. 2009;196:65-80. DOI: 10.1111/j.1748-1716.2009.01972.x.
Sahra IB, Marchand-Brustel YL, Tanti JF, Bost F. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther. 2010;9(5):1092-1099. DOI: 10.1158/1535-7163.MCT-09-1186.
Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Metformin and cancer: doses mechanisms and the dandelion and hormetic phenomena. Cell Cycle. 2010;9(6):1057-1064. DOI: 10.4161/cc.9.6.10994.
Iliopoulos D, Hirsch HA, Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res. 2011;71(9):3196-3201. DOI: 10.1158/0008-5472.CAN-10-3471.
Rocha GZ, Dias MM, Ropelle ER, Osorio-Costa F, Rossato FA, Vercesi AE, et al. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth. Clin Cancer Res. 2011;17(12):3993-4005. DOI: 10.1158/1078-0432.CCR-10-2243.
Petrushev B, Tomuleasa C, Soritau O, Aldea M, Pop T, Susman S, et al. Metformin plus PIAF combination chemotherapy for hepatocellular carcinoma. Exp Oncol. 2012;34:17-24. PMID: 22453143.
Goodwin PJ, Stambolic V, Lemieux J, Chen BE, Parulekar WR, Gelmon KA, et al. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Tret. 2011;126: 215-220. DOI: 10.1007/s10549-010-1224-1.
Chen G, Xu S, Renko K, Derwahl M. Metformin inhibits growth of thyroid carcinoma cells suppresses self-renewal of derived cancer stem cells and potentiates the effect of chemotherapeutic agents. J Clin Endocrinol Metab. 2012;97(4):510-520. DOI: 10.1210/jc.2011-1754.
Klubo-Gwiezdzinska J, Jensen K, Costello J, Patel A, Hoperia V, Bauer A, et al. Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells. Endocr Relat Cancer. 2012;19(3):447-456. DOI: 10.1530/ERC-12-0046.
Klubo-Gwiezdzinska J, Costello J, Patel A, Bauer A, Jensen K, Mete M, et al. Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer. J Clin Endocrinol Metab. 2013;98(8):3269-3279. DOI: 10.1210/jc.2012-3799.
Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. Clin. Endocr. 1998;48(3):265-273. DOI: 10.1046/j.1365-2265.1998.00392.x.
Morale MG, Tamura RE, Rubio IGS. Metformin and cancer hallmarks: molecular mechanisms in thyroid, prostate and head and neck cancer models. Biomolecules.2022;12(3):357,1-18. DOI: 10.3390/biom12030357.
Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Meth. 1989;89(2):271-277. DOI: 10.1016/0022-1759(86)90368-6.
Gerke V, Moss SE. Annexins: from structure to function. Physiol Rev. 2002;82(2):331-371. DOI: 10.1152/physrev.00030.2001.
Takac P, Kello M, Pilatova MB, Kudlickova Z, Vilkova M, Slepcikova P, et al. New chalcone derivative exhibits antiproliferative potential by inducing G2/M cell cycle arrest mitochondrial-mediated apoptosis and modulation of MAPK signalling pathway. Chem Biol Interact. 2018;292:37-49. DOI: 10.1016/j.cbi.2018.07.005.
Liang CC, Park A, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2007;2(2); 329-333. DOI: 10.1038/nprot.2007.30.
Han B, Cui H, Kang L, Zhang X, Jin Z, Lu L, et al. Metformin inhibits thyroid cancer cell growth, migration, and EMT through the MTOR pathway. Tumor Biol. 2015;36(8):6295-6304. DOI: 10.1007/s13277-015-3315-4.
Bikas A, Jensen K, Patel A, Costello J, McDaniel D, Klubo-Gwiezdzinska J, et al. Glucose-deprivation increases thyroid cancer cells sensitivity to metformin. Endocr Relat Cancer. 2015;22(6): 919-932. DOI: 10.1530/ERC-15-0402.
Coelho RG, Fortunato RS, Carvalho DP. Metabolic reprogramming in thyroid carcinoma. Front Oncol. 2018;8:82,1-15.DOI: 10.3389/fonc.2018.00082.
He Y, Cao L, Wang L, Liu L, Huang Y, Gong X. Metformin inhibits proliferation of human thyroid cancer TPC-1 cells by decreasing LRP2 to suppress the JNK pathway. Onco Targets Ther. 2020;13:45-50.DOI: 10.2147/OTT.S227915.
Shin HS, Sun HJ, Whang YM, Park YJ, Park DJ, Cho SW. Metformin reduces thyroid cancer tumor growth in the metastatic niche of bone by inhibiting osteoblastic RANKL productions. Thyroid. 2021;31(15):760-771. DOI: 10.1089/thy.2019.0851.
Durai L, Ravindran S, Arvind K, Karunagaran D, Vijayalakshmi R. Synergistic effect of metformin and vemurufenib (PLX4032) as a molecular targeted therapy in anaplastic thyroid cancer: an in vitro study. Mol Biol Rep. 2021;48(11):7443-7456. DOI: 10.1007/s11033-021-06762-7.
Kim SH, Kang JG, Kim CS, Ihm SH, Choi MG, Yoo HJ, et al. Synergistic cytotoxicity of the dipeptidyl peptidase-IV inhibitor gemigliptin with metformin in thyroid carcinoma cells. Endocrine. 2018;59(2):383-394. DOI: 10.1007/s12020-017-1503-2.
Kutbay NO, Avci CB, Yurekli BS, Kurt CC, Shademan B, Gunduz C, et al. Effects of metformin and pioglitazone combination on apoptosis and AMPK/mTOR signaling pathway in human anaplastic thyroid cancer cells. J Biochem Mol Toxicol. 2020;34(10): e22547,1-11. DOI: 10.1002/jbt.22547.
Montecucco A, Zanetta F, Biamonti G. Molecular mechanisms of etoposide. EXCLI J. 2015;14:95-108. DOI: 10.17179/excli2015-561.
Cersosimo RJ, Hong WK. Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol. 1986;4(3):425-439. DOI: 10.1200/JCO.1986.4.3.425.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.